Fuhong Hanlin (02696) had revenue of 3,588.2 billion yuan in the first half of the year, and overseas product sales revenue increased 159.4% year-on-year

Zhitong Finance App learned that on August 21, Fuhong Hanlin (02696) announced that in the first half of 2026, the company achieved revenue of RMB 3,588.2 billion, an increase of 27.3% over the previous year; net profit of RMB 430.4 million, an increase of 10.3% over the previous year. In the first half of 2026, the company's non-IFRS profit reached $572.3 million, up 46.7% year on year; non-IFRS adjusted profit before interest, tax, depreciation and amortization (EBITDA) reached 904.1 million yuan, up 35.2% year on year.

Currently, the company has 10 products approved for sale in more than 60 countries and regions around the world, covering a wide range of Asia, Europe, Latin America, North America and Oceania, benefiting more than 1.1 million patients. In the first half of 2026, the company's global product sales revenue reached 2,9386 million yuan, up 14.9% year on year. Overseas product sales revenue increased 159.4% year on year to 105.3 million yuan, and overseas product sales profit was 595 million yuan, more than four times that of the same period last year. The company's Globalization 2.0 strategy has entered a critical accelerated verification cycle.

On the same day, Hang Seng Index Limited's latest quarterly review results were announced. Fu Hong Hanlin was officially selected as a constituent stock of the Hang Seng Composite Index, which will take effect from September 7, 2026. After being included in the index, Fu Hong Hanlin's H shares are expected to meet the transfer standards for Hong Kong Stock Connect shares under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. It is expected to further expand the company's investor base in the mainland capital market, attract the attention of mainland and international long-term value investors, and enhance the liquidity of stock trading.